Abstract: The invention relates to small granules comprising cholestyramine. The granules have a high cholestyramine content and are stable enough to be coated with one or more coating layers. The invention also relates to a multiparticulate drug delivery system comprising such granules. The invention further relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine granules that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption and bile acid diarrhoea.
Type:
Application
Filed:
September 7, 2018
Publication date:
March 7, 2019
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Kurt Lövgren
Abstract: The present invention provides methods for treating an inflammatory brain disease and for treating a traumatic brain injury in a human having an inflammatory component applying transdermal pharmaceutical compositions comprising chromium, magnesium, and thiamine as active ingredient compounds that act as neuroprotective iron chelators and brain glucose-uptake enhancement that are suitable for the treatment of traumatic brain injury. The invention further relates to methods of delivering the pharmaceutical compositions that target the brain and/or central nervous system certain novel iron chelators of the type described in the specification.
Abstract: A homeopath nasal spray, swab or gel solution is provided. The composition includes a 1× to 6× (3C) dilution of argentum nitricum, 10× to 30× (5C to 15C), and any other higher or LM potencies, dilution of at least one of an additional argentum compound selected from the group consisting of argentum cyanatum, argentum iodatum, argentum metallicum, argentum muriaticum, argentum oxydatum and argentum phosphoricum; and, 10× to 30× (5C to 15C), and any other higher or LM potencies, dilution of at least one homeopathic compound for reducing various health conditions.
Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
Type:
Application
Filed:
July 7, 2016
Publication date:
March 7, 2019
Applicants:
The University of Sydney, Western Sydney Local Health District
Abstract: The present disclosure includes compositions, methods, and uses for a subset of T cells, SP T (TSP) cells, which display a quiescent (G0) phenotype. Aspects of the disclosure include methods for obtaining and mobilizing TSP cells in a subject. Other aspects include methods of adoptive cell transfer in a subject utilizing TSP cells.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Application
Filed:
November 15, 2018
Publication date:
March 7, 2019
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention relates to a selection method of a highly active stem cell for treatment of cerebrovascular diseases, comprising a step of measuring a level of a neurotrophic factor, and a highly active stem cell selected thereby. According to the present invention, BDNF secreted by mesenchymal stem cells mediate inhibitory effects on cell death, inflammation, astrogliosis, and posthemorrhagic hydrocephalus and plays a very important role in improving myelination after intraventricular hemorrhage. Hence, the method according to the present invention can be usefully applied to the treatment of various cerebrovascular diseases including intraventricular hemorrhage in preterm infants.
Type:
Application
Filed:
March 30, 2017
Publication date:
March 7, 2019
Applicant:
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
Inventors:
Yun Sil CHANG, Won Soon PARK, So Yoon AHN, Dong Kyung SUNG
Abstract: A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.
Abstract: The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.
Abstract: Embodiments of the disclosure concern methods and compositions related to manipulation of the microbiome in an individual having at least one social behavior deficit. In particular embodiments, an individual has at least one social behavior deficit and was born from a mother who during pregnancy was obese, overweight, or on a high-fat diet during pregnancy or carries mutations associated with neurodevelopmental disorders. In specific embodiments, the individual having at least one social behavior deficit is provided an effective amount of Lactobacillus reuteri for the improvement of at least one symptom of a social behavior deficit.
Type:
Application
Filed:
April 15, 2017
Publication date:
March 7, 2019
Inventors:
Mauro Costa-Mattioli, Shelly Alexandra Buffington
Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
Type:
Application
Filed:
October 12, 2018
Publication date:
March 7, 2019
Inventors:
Colleen CUTCLIFFE, John S. EID, James H. BULLARD, Marcus F. SCHICKLBERGER
Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
Type:
Application
Filed:
October 12, 2018
Publication date:
March 7, 2019
Inventors:
Colleen CUTCLIFFE, John S. EID, James H. BULLARD, Marcus F. SCHICKLBERGER
Abstract: A composition comprising combination of salt, sugar and lactic acid bacteria as an active ingredient to treat vaginosis. The composition showed potent antibacterial activity through various experiments, for example, (1) the indirect inhibitory activity test from the growth of vaginosis causing bacteria by determining the change of pH and lactic acid level; (2) the direct inhibitory activity test from the growth of vaginosis causing bacteria by determining the susceptibility of test sample; (3) brief clinical tests, and finally confirmed that the combination showed potent antibacterial activity in the test. Accordingly, the combination may be useful to alleviate and treat vaginosis in the form of a pharmaceutical composition, health functional food, food additive, topical composition, and detergent composition.
Abstract: An object of the present invention is to provide a lactic acid bacterium that inhibits secondary fermentation of silage and proves useful in the preparation of preferable silage. Another object of the present invention is to provide a method for manufacturing silage whose secondary fermentation is inhibited. As a means for achieving the objects, a Lactobacillus diolivorans having anti-yeast action is provided as a lactic acid bacterium for preparing silage.
Abstract: The present invention relates to a new cocktail of bacteriophages with specific lytic activity against Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B., for reducing, eliminating and/or preventing them in farm animals and animals from the poultry sector, such as poultry, hens and breeding hens, in addition to eggs. It may be administered as an additive in the feed, in water or by spray. Moreover, the cocktail may be used as a disinfectant in work areas of farms and abattoirs, and in processed foods, without affecting the organoleptic properties of the product.
Type:
Application
Filed:
November 21, 2016
Publication date:
March 7, 2019
Inventors:
Martha Josefina VIVES FLOREZ, Ana Paula JIMENEZ SANCHEZ, Angela Victoria HOLGUIN MORENO
Abstract: Disclosed herein are novel methodologies for cloning prophage genome sequences that are identified from target organisms or DNA sequencing data and that contain mutations that decrease the function of prophage repressor proteins and for producing lytic phage particles with decreased prophage repressor protein function.
Type:
Application
Filed:
March 5, 2018
Publication date:
March 7, 2019
Applicant:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Timothy Kuan-Ta LU, Robert James CITORIK
Abstract: The present invention provides methods for treating an individual having solid or lymphatic tumor comprising locally administering to the site of the tumor an oncolytic virus, and systemically administering an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor a second immunomodulator (including a combination of immunomodulators). Also provided are compositions and kits for the cancer therapy methods.
Abstract: A method for introducing a fermented product to poultry to reduce foodborne pathogens. The fermented product contains functional metabolites produced by Saccharomyces cerevisiae and is added at a particular ratio to the feed for the most effective results.
Abstract: A method for treating hepatitis B comprises administering a herbal extract to a subject in need thereof to suppress survival of hepatitis B virus. The herbal extract is manufactured by extracting a herbal composition by a 70-95% aqueous ethanol solution at 40-50° C. The herbal composition comprises 40 wt % of a fruit body sample of Antrodia cinnamomea, 40 wt % of a sample of Polygonatum sibiricum and 20 wt % of a sample of Glycyrrhiza uralensis.
Abstract: The present disclosure relates to the field of drugs and health foods. Disclosed is a traditional Chinese medicine composition comprising GANODERMA polysaccharide, MORINDAE OFFICINALIS RADIX polysaccharide, POLYGONATI RHIZOMA polysaccharide, ANGELICAE SINENSIS RADIX oil and MYRISTICAE SEMEN oil. Experiments show that the traditional Chinese medicine composition has a scientific formulation, synergistic functions, without toxic and side effects, and not only has nutritional value but also inhibits the growth of tumor. Comparing with individual components, the composition significantly increases the percentages of CD4+ and CD8+ cells in lymphocytes of the tumor stroma, enhances body immune function, restores normal immune surveillance function, decreases VEGF and TGF-?1 positive cells in tumor tissue, assists in treating tumor, increases antitumor effects of chemotherapy drugs, improves immune status of body, has the function of restoring normal immune surveillance, preventing and assisting in treating tumor.
Abstract: The present disclosure relates to the field of drugs and health foods. Disclosed is a traditional Chinese medicine composition comprising GANODERMA polysaccharide, GRIFOLA FRONDOSA polysaccharide, ANGELICAE SINENSIS RADIX oil and CINNAMOMI CORTEX oil. Experiments show that the traditional Chinese medicine composition has a scientific formulation, synergistic functions, without toxic and side effects, and not only has nutritional value but also inhibits the growth of tumor. Comparing with individual components, the composition significantly increases the percentages of CD4+ and CD8+ cells in lymphocytes of the tumor stroma, increases body immune function, recovers normal immune surveillance function, decreases the expression rate of VEGF and TGF-? 1 positive cells in tumor tissue, assists in treating tumor, increases antitumor effects of chemotherapy drugs, improves immune status of body, has the function of restoring normal immune surveillance, preventing and assisting in treating tumor.
Abstract: A human oral at least partly enteric formulation comprising one or more jojoba components, for controlling, stimulating or modulating functions for patients suffering from a degenerative disease, or for patients at risk from suffering from a degenerative disease, or for patients under therapeutic treatment of a degenerative disease.
Abstract: An edible herbal formulation which raises the alkalinity of the human body in a short period of time is disclosed. The major ingredient in the formulation is Camptotheca. Additional ingredients that may be included are poria cocos, astragalus membranacaus, ostrea vivularis gould, prunella vulgaris, bombyx mori and phellodendron amurense Rupr. While the herbal formulation may be a mixture containing Camptotheca and all or some of the above ingredients, it is most preferred that the herbal formulation include the three ingredients of Camptotheca, poria cocos and astragalus membranacaus.
Abstract: A gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout is prepared by mixing raw materials of gynostemma pentaphyllum, folium eucommiae, folium mori, semen plantaginis, herba lophatheri, pueraria mirifica powder, pelargonium graveolens and sanguisorba minor, and the raw materials are in percentage by mass: 40-70% of gynostemma pentaphyllum, 5-20% of folium eucommiae, 5-20% of folium mori, 5-10% of semen plantaginis, 2-10% of herba lophatheri, 2-10% of pueraria mirifica powder, 2-8% of pelargonium graveolens and 2-8% of sanguisorba minor. The gynostemma pentaphyllum is prepared by mixing diploid gynostemma pentaphyllum leaves and tetraploid gynostemma pentaphyllum leaves according to a ratio.
Type:
Application
Filed:
November 8, 2018
Publication date:
March 7, 2019
Inventors:
Shaoke WANG, Theresa Y Y TSE, Zhao ZHANG
Abstract: The present invention relates to a composition for alleviating, preventing, or treating menopausal symptoms and/or osteoporosis. The composition of the present invention is rapidly effective in preventing or alleviating menopausal symptoms, and thus may be usefully used in conventional hormone replacement therapies (HRTs) used to prevent or alleviate menopausal symptoms. In addition, the composition of the present invention has no toxicity, can be used as food due to few side effects, and is safe, unlike conventional therapeutic agents for menopausal symptoms, and thus may be more effectively used as compared to conventional therapeutic agents for menopausal symptoms.
Type:
Application
Filed:
September 6, 2017
Publication date:
March 7, 2019
Applicant:
LG Household & Health Care Ltd.
Inventors:
Youn Jung LEE, Ho Song CHO, Won Kyung LEE, Soon Ran SONG, Sang Hwa LEE
Abstract: Is herein described a nanoparticle ophthalmic composition comprising at least 0.1% of Perilla frutescens extract and at least 0.1% of hyaluronic acid or a salt thereof wherein the Perilla frutescens extract has a content of polyphenols of at least 2.5% by weight of the total weight of the extract and to the use of said ophthalmic composition in the treatment of ocular disorders or diseases such as tear dysfunction syndrome, dry eye, diabetic retinopathy and glaucoma, preferably in the treatment of tear dysfunction syndrome.
Abstract: The objective of the present invention is to provide a safe muscle-enhancing agent by which a muscle mass and muscular strength can be effectively increased or maintained and by which a decrease of a muscle mass and muscular strength can be suppressed, a muscle-enhancing composition containing the muscle-enhancing agent, and a method for enhancing muscle by using the muscle-enhancing agent or muscle-enhancing composition. The muscle-enhancing agent according to the present invention is characterized in comprising an extract derived from lemon myrtle as an active ingredient.
Abstract: The present disclosure encompasses compositions prepared from Boysenberry. Also encompassed are methods of preparing these compositions and methods of using these compositions, in particular, for treating or preventing disorders of the respiratory system, including amongst others: inflammation, asthma, chronic obstructive pulmonary disease, reactive airway disease, airway fibrosis, and airway remodeling.
Abstract: The present document describes a nutriprotective diet comprising a nutriprotective amount of a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, or combinations thereof. The present document also describes a method of eliciting a nutriprotective effect in a subject, which comprises administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document also describes a method of treating a subject with a disorder, by administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document describes a process for the extraction of polyphenolic compounds from maple syrup using adsorbent materials, and the extracts obtained therefrom.
Type:
Application
Filed:
August 23, 2018
Publication date:
March 7, 2019
Applicant:
FÉDÉRATION DES PRODUCTEURS ACÉRICOLES DU QUÉBEC
Inventors:
Steeves POTVIN, Vincent BÉDARD, François BÉLAND, Geneviève BÉLAND, Keiko ABE
Abstract: The present disclosure relates to the field of drugs and health foods. Disclosed is a traditional Chinese medicine composition comprising LYCII FRUCTUS polysaccharide, POLYGONATI RHIZOMA polysaccharide, CARYOPHYLLI FLOS oil and CINNAMOMI CORTEX oil. Experiments show that the traditional Chinese medicine composition has a scientific formulation, synergistic functions, without toxic and side effects, and not only has nutritional value but also inhibits the growth of tumor. Comparing with individual components, the composition significantly increases the percentages of CD4+ and CD8+ cells in lymphocytes of the tumor stroma, increases body immune function, recovers normal immune surveillance function, decreases the expression rate of VEGF and TGF-? 1 positive cells in tumor tissue, assists in treating tumor, increases antitumor effects of chemotherapy drugs, improves immune status of body, has the function of restoring normal immune surveillance, preventing and assisting in treating tumor.
Abstract: Compositions and Methods for the Treatment of Amyloid Deposit diseases, e.g., Hereditary cystatin C amyloid angiopathy and other neurodegenerative disorders, are disclosed.
Type:
Application
Filed:
September 7, 2018
Publication date:
March 7, 2019
Inventors:
Hakon Hakonarson, Alvaro Gutierrez-Uzquiza, Michael March
Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3?). These molecules compete with CD3? for binding to a CD3? binding domain. e.g. a CD3? binding domain of an antibody, and are capable of detecting antibodies against CD3?. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3? antibody purification and the detection of anti-CD3? antibodies in biological samples.
Type:
Application
Filed:
July 14, 2015
Publication date:
March 7, 2019
Inventors:
Ugur Sahin, Laura Marie Kring, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt, Ulf Reimer, Karsten Schnatbaum
Abstract: A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.
Type:
Application
Filed:
November 2, 2018
Publication date:
March 7, 2019
Inventors:
Jacinth Kincaid Fairley, Colin Paul Barrett, Jeremy Robert Arthur Paull
Abstract: The present invention relates, rider alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
Type:
Application
Filed:
April 28, 2017
Publication date:
March 7, 2019
Inventors:
Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.
Type:
Application
Filed:
November 6, 2018
Publication date:
March 7, 2019
Applicants:
The Population Council, Inc., The United States of America
Inventors:
Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
Abstract: The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject.
Type:
Application
Filed:
April 5, 2018
Publication date:
March 7, 2019
Inventors:
Robert L. GOLDSTEIN, Grant DUBOIS, Arianne PERRY
Abstract: This invention pertains to the identification of antibody mediated epitope mimics and applications of the identification of said mimic peptides in the design of biotherapeutics and vaccines.
Abstract: Systems and methods for preparing synthetic osteoinductive bone grafts are provided in which a porous ceramic granule, which may be incorporated within a biocompatible matrix material, is loaded with an osteoinductive agent. Loading of granules is facilitated in some cases by the use of low-pH buffers and pre-treatments.
Type:
Application
Filed:
October 4, 2018
Publication date:
March 7, 2019
Inventors:
Eric Vanderploeg, Howard Seeherman, Christopher G. Wilson, John Wozney, Christopher T. Brown, John A. Kambouris
Abstract: The present specification is directed to systems, apparatus and methods for prophylactically preventing, or for treating the progression of, Alzheimer's disease. The progression of, stabilizing, or improving Symptoms related to Alzheimer's Disease (AD) are treated by monitoring a pathophysiological change indicative of AD in a patient, based on the monitoring, determining if amyloid plaque is present in a perivascular space of the patient, optionally determining an extent of amyloid plaque in the perivascular space, and based on the presence of amyloid plaque in the perivascular space of the patient, determining a treatment protocol for the patient. The treatment protocol includes administering to the patient a high density lipoprotein composition derived from mixing a blood fraction with a lipid removing agent.
Type:
Application
Filed:
March 1, 2018
Publication date:
March 7, 2019
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of Zn-?2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.
Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.
Type:
Application
Filed:
October 7, 2016
Publication date:
March 7, 2019
Inventors:
Joshua Schiffman, Avi Schroeder, Lisa Abegglen
Abstract: The present disclosure relates to suppression of cellular transformation and dysplasia by topical application of Lefty. In particular, the present disclosure provides compositions and methods for topically applying Lefty to treat and prevent cancers.
Abstract: The subject invention provides materials and methods for modulating cellular glucose uptake. Specifically, in accordance with one embodiment of the subject invention, stem cell factor (SCF) can be used to stimulate cellular glucose uptake. The administration of SCF can also be used to promote Glucose Transporter 4 (GLUT4) expression. In accordance with the subject invention, SCF can be used to improve glucose homeostasis, including in the treatment of diabetes mellitus.
Abstract: The present invention provides compositions and methods comprising an activator of IL-18 activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP.
Abstract: Embodiments relate to peptide antagonists of -family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of -cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual -cytokine family member/? receptor subunit. However, success has been limited and often multiple -cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus -subunit binding site to inhibit -cytokine activity.
Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.